Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,057 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI. Amadori D, et al. Among authors: ibrahim t. Lancet Oncol. 2013 Jun;14(7):663-70. doi: 10.1016/S1470-2045(13)70174-8. Epub 2013 May 16. Lancet Oncol. 2013. PMID: 23684411 Clinical Trial.
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.
Santini D, Procopio G, Porta C, Ibrahim T, Barni S, Mazzara C, Fontana A, Berruti A, Berardi R, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, Virzì V, Santoni M, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Fedeli SL, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Tonini G, Bracarda S. Santini D, et al. Among authors: ibrahim t. PLoS One. 2013 Dec 30;8(12):e83026. doi: 10.1371/journal.pone.0083026. eCollection 2013. PLoS One. 2013. PMID: 24386138 Free PMC article.
Targeting bone metastatic cancer: Role of the mTOR pathway.
Bertoldo F, Silvestris F, Ibrahim T, Cognetti F, Generali D, Ripamonti CI, Amadori D, Colleoni MA, Conte P, Del Mastro L, De Placido S, Ortega C, Santini D. Bertoldo F, et al. Among authors: ibrahim t. Biochim Biophys Acta. 2014 Apr;1845(2):248-54. doi: 10.1016/j.bbcan.2014.01.009. Epub 2014 Feb 5. Biochim Biophys Acta. 2014. PMID: 24508774 Review.
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, Guida FM, Fontana A, Berruti A, Berardi R, Massari F, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, De Lisi D, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Luzi Fedeli S, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Montironi R, Bracarda S, Tonini G, Cascinu S, Santini D. Santoni M, et al. Among authors: ibrahim t. J Exp Clin Cancer Res. 2015 Feb 5;34(1):10. doi: 10.1186/s13046-015-0122-0. J Exp Clin Cancer Res. 2015. PMID: 25651794 Free PMC article.
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.
Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G. Santini D, et al. Among authors: ibrahim t. Sci Rep. 2015 Dec 22;5:18670. doi: 10.1038/srep18670. Sci Rep. 2015. PMID: 26690845 Free PMC article.
Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events.
Grisanti S, Bianchi S, Locati LD, Triggiani L, Vecchio S, Bonetta A, Bergamini C, Conte P, Airoldi M, Merlano M, Carlini P, Ibrahim T, Rossetto C, Alfieri S, Pronzato P, Tonoli S, Maroldi R, Nicolai P, Resteghini C, Magrini SM, Berruti A. Grisanti S, et al. Among authors: ibrahim t. PLoS One. 2019 Mar 20;14(3):e0213934. doi: 10.1371/journal.pone.0213934. eCollection 2019. PLoS One. 2019. PMID: 30893350 Free PMC article.
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A, Liverani C, Pusceddu S, Leo S, Di Meglio G, Tamberi S, Santini D, Gelsomino F, Pucci F, Berardi R, Lolli I, Bergamo F, Ricci S, Foca F, Severi S, Ibrahim T; SENECA Study Team Investigators. Bongiovanni A, et al. Among authors: ibrahim t. BMJ Open. 2020 Jul 19;10(7):e034393. doi: 10.1136/bmjopen-2019-034393. BMJ Open. 2020. PMID: 32690499 Free PMC article.
1,057 results